These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9483232)

  • 21. The evidence behind inhibitor treatment with porcine factor VIII.
    Lee CA
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():5-8. PubMed ID: 12214138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party.
    Hay CR; Ollier W; Pepper L; Cumming A; Keeney S; Goodeve AC; Colvin BT; Hill FG; Preston FE; Peake IR
    Thromb Haemost; 1997 Feb; 77(2):234-7. PubMed ID: 9157572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
    Abou-Ismail MY; Vuyyala S; Prunty J; Schmaier AH; Nayak L
    Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
    Astermark J; Voorberg J; Lenk H; DiMichele D; Shapiro A; Tjönnfjord G; Berntorp E
    Haemophilia; 2003 Sep; 9(5):567-72. PubMed ID: 14511295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Innovative use of porcine factor VIII:C for immune tolerance induction.
    Hay CR
    Am J Med; 1991 Nov; 91(5A):27S-29S. PubMed ID: 1746593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
    Kruse-Jarres R; St-Louis J; Greist A; Shapiro A; Smith H; Chowdary P; Drebes A; Gomperts E; Bourgeois C; Mo M; Novack A; Farin H; Ewenstein B
    Haemophilia; 2015 Mar; 21(2):162-170. PubMed ID: 25623166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII.
    Ekert H; Price DA; Lane JL; Dean FL
    Aust N Z J Med; 1979 Jun; 9(3):241-4. PubMed ID: 288389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Factor VIII inhibitors in patients suffering from severe haemophilia A: problems of "very low" responders].
    Lutze G; Aumann V; Lutze G; Mittler U
    Klin Padiatr; 2001; 213(6):321-4. PubMed ID: 11713709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.
    Yee TT; Taher A; Pasi KJ; Lee CA
    Clin Lab Haematol; 2000 Oct; 22(5):275-8. PubMed ID: 11122268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired haemophilia and haemostatic control with recombinant porcine factor VIII: case series.
    Campbell S; Mason J; Prasad R; Ambrose H; Hunt S; Tran H
    Intern Med J; 2021 Feb; 51(2):215-219. PubMed ID: 32043744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of factor VIII in black patients with hemophilia.
    Viel KR; Ameri A; Abshire TC; Iyer RV; Watts RG; Lutcher C; Channell C; Cole SA; Fernstrom KM; Nakaya S; Kasper CK; Thompson AR; Almasy L; Howard TE
    N Engl J Med; 2009 Apr; 360(16):1618-27. PubMed ID: 19369668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health economics of treating haemophilia A with inhibitors.
    Knight C
    Haemophilia; 2005 Nov; 11 Suppl 1():11-7. PubMed ID: 16219044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.